1- Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
2- Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran , soltanib@modares.ac.ir
3- Clinical Genetics Department, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
4- Breast Cancer Research Center, Iranian Center for Breast Cancer (ICBC) Academic Center for Education, Culture and Research (ACECR). Tehran, Iran
Abstract: (2038 Views)
Breast cancer is the leading cause of cancer-related mortality among women worldwide. In Iran, breast cancer ranks first among cancers diagnosed in women comprising 24.4% of all malignancies. Currently, the large number of etiological factors and the complexity of breast cancer present challenge for prevention and treatment. Breast cancer tumorigenesis can be described as a multi-step process in which a normal cell undergoes malignant transformation to a fully developed tumor through accumulations of genetic and epigenetic changes, on the other hand, Several studies indicated the signaling pathways role in Breast cancer. EGFR gene has been shown to be overexpressed in breast cancer .Dimerization of EGFR/HER2 induces breast cancer progression via activation of PI3K/AKT signaling cascade
MicroRNAs are endogenous, small non-coding RNAs that regulate gene expression at the transcriptional and posttranscriptional level. MicroRNAs pair with partially complementary sites in the 3′untranslated regions (UTRs) of target mRNAs, leading to translational repression and/or mRNA degradation. They play important roles in several cellular processes, such as proliferation, differentiation, apoptosis, and development, by simultaneously controlling the expression level of hundreds of genes. Here we demonstrated the tumor suppression effect of miR-1226-3p in Breast cancer by targeting EGFR oncogene.
Article Type:
Original Research |
Subject:
Molecular biotechnology Received: 2018/10/2 | Accepted: 2019/01/14 | Published: 2022/11/28